news semaglutide A pilot program will cover weight-loss drugs for millions of Medicare enrollees for the first time beginning July 1. Read more about who's eligible and what medications are included at the link FDA approves pill version of

The appropriate reporting checklist for this study design was followed (STROBE)

To qualify, a person must be enrolled in a Medicare Part D plan and meet one of three clinical criteriaassessed at the time you first started GLP-1 therapy, not at the time you apply: BMI of 35 or higher (no additional diagnosis required) BMI of 30 or higher, plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension on two or more blood pressure medications, or chronic kidney disease stage 3a or higher BMI of 27 or higher, plus a diagnosis of pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease Your provider submits a prior authorization request attesting you meet the criteriayou dont need to opt in or take any action yourself

Weight Loss Specific Brands: Mounjaro vs Wegovy/Ozempic Mounjaro was FDA-approved in May 2022 for adults with type 2 diabetes, while Zepbound received approval in November 2023 for chronic weight management

Heres what you get with us and what you wont find anywhere else

Both have reshaped treatment landscapes by targeting gut hormones to improve glycemic control and curb appetite